Langerhans Cells Release Prostaglandin D2 in Response to Nicotinic Acid

• Published in: Journal of investigative dermatology Vol. 126; no. 12; pp. 2637 - 2646
• Main Authors: Maciejewski-Lenoir, Dominique, Richman, Jeremy G., Hakak, Yaron, Gaidarov, Ibragim, Behan, Dominic P., Connolly, Daniel T.
• Format: Journal Article
• Language: English
• Published: Danvers, MA Elsevier Inc 01.12.2006; Nature Publishing; Elsevier Limited
• Subjects: Animals; Biological and medical sciences; Cells, Cultured; Dermatology; Flushing - chemically induced; Humans; Hypolipidemic Agents - pharmacology; In Vitro Techniques; Langerhans Cells - drug effects; Langerhans Cells - metabolism; Male; Medical sciences; Mice; Mice, Inbred C57BL; Niacin - pharmacology; Oligonucleotide Array Sequence Analysis; Prostaglandin D2 - metabolism; Receptors, G-Protein-Coupled - genetics; Receptors, G-Protein-Coupled - metabolism; Receptors, Nicotinic - genetics; Receptors, Nicotinic - metabolism; RNA, Messenger - metabolism; Skin - metabolism; Tissue Distribution; Langerhans cell; Antigen presenting cell; Dermatology; Nicotinic acid; B-Vitamins; Prostaglandin D2; Release; Pyridine derivatives; Antilipemic agent
• ISSN: 0022-202X; 1523-1747
• DOI: 10.1038/sj.jid.5700586

Nicotinic acid, used for atherosclerosis treatment, has an adverse effect of skin flushing. The flushing mechanism, thought to be caused by the release of prostaglandin D2 (PGD2), is not well understood. We aimed to identify which cells mediate the flushing effect. Nicotinic acid receptor (GPR109A) gene expression was assessed in various tissues and cell lines. Cells expressing GPR109A mRNA were further assayed for PGD2 release in response to nicotinic acid. Of all samples, only skin was able to release PGD2 upon stimulation with nicotinic acid. The responsive cells were localized to the epidermis, and immunocytochemical studies revealed the presence of GPR109A on epidermal Langerhans cells. CD34+ cells isolated from human blood and differentiated into Langerhans cells (hLC-L) also showed GPR109A expression. IFNγ treatment increased both mRNA and plasma membrane expression of GPR109A. IFNγ-stimulated hLC-Ls released PGD2 in response to nicotinic acid in a dose-dependant manner (effector concentration for half-maximum response=1.2mm±0.7). Acifran, a structurally distinct GPR109A ligand, also increased PGD2 release, whereas isonicotinic acid, a nicotinic acid analog with low affinity for GPR109A, had no effect. These results suggest that nicotinic acid mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of PGD2.